Crossmark

PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL

Published Online: 2024-07-20

Authors

Lahera, Antonio https://orcid.org/0000-0002-8899-1376
Vela-Martín, Laura https://orcid.org/0000-0001-9435-8668
Fernández-Navarro, Pablo

Llamas, Pilar

López-Lorenzo, José L. https://orcid.org/0000-0003-1502-3902
Cornago, Javier

Santos, Javier

Fernández-Piqueras, José

Villa-Morales, María https://orcid.org/0000-0001-7906-0169
License Information

Text and Data Mining valid from 2024-07-20

Version of Record valid from 2024-07-20
More Information

Article History

Received: 18 October 2023

Accepted: 9 July 2024

First Online: 20 July 2024

Competing interests

: The authors declare no competing interests.

Document is current